- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Caprius debuts as Advanced NMR's progeny
MRI developers Advanced NMR and Advanced Mammography Systems have chosen the RSNA meeting to make their debut as Caprius (Hall B, #7358), the new entity that represents the merger of the two firms. Shareholders approved the merger Nov. 11 in a deal that
MRI developers Advanced NMR and Advanced Mammography Systems have chosen the RSNA meeting to make their debut as Caprius (Hall B, #7358), the new entity that represents the merger of the two firms. Shareholders approved the merger Nov. 11 in a deal that dissolves Advanced Mammography Systems and incorporates its assets into Advanced NMR, which had been a major shareholder in AMS prior to the agreement.
The merger permits Caprius to build on the strengths of both companies, according to Jack Nelson, CEO of the Wilmington, MA, vendor. Advanced NMR is cash-rich and experienced in opening breast imaging centers, he said, while AMS owns the rights to the industry's only dedicated MR mammography scanner cleared by the Food and Drug Administration, the 0.5-tesla Aurora system.
Caprius is developing joint-venture MR breast imaging collaborations with clinical sites that have the Aurora system. The Faulkner-Sagoff Centre for Breast Health Care, the first such commercial breast imaging venture, opened earlier this month in Boston. A test site has operated since April 1996 at the University of Texas in Galveston.
On the new technology front, Caprius will describe the introduction of RODEO, a fat-suppressed pulse sequence specifically developed for breast imaging by Dr. Steven Harms. Progress with its investigation MRI-guided breast biopsy system will also be covered.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
